AFFiRiS AG has Presented Phase I Data on The Trial for the First Parkinson's Vaccine Candidate

First Clinical Data of Therapeutic Parkinson’s Vaccine is Encouraging

AFFiRiS AG has Presented Phase I Data on a Trial for the First Parkinson’s Vaccine Candidate On the 31st of July 2014, AFFiRiS AG announced as a press conference the results of their phase I clinical trial for a vaccine against Parkinson’s disease.  The vaccine, PD01A, is a therapy that targets the alpha-synuclein protein, a Parkinson’s target. The Michael J.Fox …

Parkinson’s Vaccine – Top Experts Unite in European Consortium

April 28, 2014 An international consortium of top European research teams has received significant EU funding for the development of therapeutic vaccines against Parkinson’s Disease (PD) and Multiple System Atrophy (MSA). Led by the Austrian biotech company AFFiRiS AG, the consortium will use a novel tandem strategy to advance the development of two therapeutic vaccine candidates in parallel. They are …